ADx NeuroSciences

Ghent, Belgium Founded: 2011 • Age: 15 yrs
Biomarker assays for neurodegenerative diseases are developed using custom antibodies.
Request Access

About ADx NeuroSciences

ADx NeuroSciences is a company based in Ghent (Belgium) founded in 2011.. ADx NeuroSciences has raised $3.17 million across 4 funding rounds from investors including European Union. The company has 14 employees as of December 31, 2021. ADx NeuroSciences offers products and services including Biomarker Assays and Tailor-made Antibodies. ADx NeuroSciences operates in a competitive market with competitors including Cytox, Amprion, PeopleBio R&D, Durin Technologies and Adlyfe, among others.

  • Headquarter Ghent, Belgium
  • Employees 14 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Adx Neurosciences
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $3.17 M (USD)

    in 4 rounds

  • Latest Funding Round
    $588.08 K (USD), Grant

    Nov 01, 2019

  • Investors
  • Employee Count
    14

    as on Dec 31, 2021

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of ADx NeuroSciences

ADx NeuroSciences offers a comprehensive portfolio of products and services, including Biomarker Assays and Tailor-made Antibodies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Assays for quantifying biomarkers in neurodegenerative diseases

Custom antibodies for detecting specific disease markers

Funding Insights of ADx NeuroSciences

ADx NeuroSciences has successfully raised a total of $3.17M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $588.08 thousand completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Grant — $588,080
  • First Round

    (12 Jul 2012)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2019 Amount Grant - ADx NeuroSciences Valuation

investors

Mar, 2016 Amount Series B - ADx NeuroSciences Valuation

investors

Aug, 2013 Amount Series A - ADx NeuroSciences Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in ADx NeuroSciences

ADx NeuroSciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by ADx NeuroSciences

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - ADx NeuroSciences

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Adx Neurosciences Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of ADx NeuroSciences

ADx NeuroSciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cytox, Amprion, PeopleBio R&D, Durin Technologies and Adlyfe, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Prognostic tests for assessing dementia risk are developed.
domain founded_year HQ Location
Assay technology for misfolded proteins in neurodegenerative disorders is developed.
domain founded_year HQ Location
Immunoassays are developed for early detection of neurodegenerative diseases.
domain founded_year HQ Location
Developer of the diagnostic test for neurodegenerative diseases
domain founded_year HQ Location
Develops biomarkers and diagnostic tests for amyloid-related diseases.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Adx Neurosciences

Frequently Asked Questions about ADx NeuroSciences

When was ADx NeuroSciences founded?

ADx NeuroSciences was founded in 2011 and raised its 1st funding round 1 year after it was founded.

Where is ADx NeuroSciences located?

ADx NeuroSciences is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.

Is ADx NeuroSciences a funded company?

ADx NeuroSciences is a funded company, having raised a total of $3.17M across 4 funding rounds to date. The company's 1st funding round was a Series A of $1.33M, raised on Jul 12, 2012.

How many employees does ADx NeuroSciences have?

As of Dec 31, 2021, the latest employee count at ADx NeuroSciences is 14.

What does ADx NeuroSciences do?

ADx NeuroSciences was founded in 2011 in Ghent, Belgium, within the biotechnology sector focused on neurodegenerative diseases. Biomarker assays are developed to detect indicators such as beta amyloid and tau in patient fluid samples, primarily cerebrospinal fluid, with emerging blood-based tests. Panels target Alzheimers disease, alongside Parkinsons disease, traumatic brain injury, and amyotrophic lateral sclerosis. Partnerships are maintained with Quanterix, Lilly, TauRx, and EuroImmun to support assay advancement.

Who are the top competitors of ADx NeuroSciences?

ADx NeuroSciences's top competitors include Amprion, PeopleBio R&D and Cytox.

What products or services does ADx NeuroSciences offer?

ADx NeuroSciences offers Biomarker Assays and Tailor-made Antibodies.

Who are ADx NeuroSciences's investors?

ADx NeuroSciences has 1 investor. Key investors include European Union.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available